In $1.36B biobuck deal with GSK, Mer­sana touts 'biggest pre­clin­i­cal ADC deal ever'

Days af­ter En­her­tu reeled in an­oth­er FDA nod, with the first-ever green light for HER2-low breast can­cer, an­oth­er an­ti­body drug con­ju­gate biotech claims it has se­cured the largest pre­clin­i­cal ADC pact to date for a sin­gle as­set.

As­traZeneca and Dai­ichi Sankyo made waves with their near­ly $7 bil­lion col­lab­o­ra­tion back in spring 2019, but at that point, En­her­tu was al­ready near­ing the FDA’s doors with clin­i­cal da­ta. The lat­est ADC tie-up to en­ter the bio­phar­ma fray cen­ters around a pre­clin­i­cal as­set, Mer­sana Ther­a­peu­tics’ XMT-2056.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN